by B2i | Apr 29, 2021 | Press Releases
JUPITER, FL / April 29, 2021 / Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its...
by B2i | Apr 22, 2021 | Press Releases
Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern TimeJUPITER, Fla., April 22, 2021 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:DYAI), a global...
by B2i | Mar 30, 2021 | Press Releases
Advancing Dyadic’s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and accelerate C1 adoption and commercialization To serve as proof of concept for...
by B2i | Mar 29, 2021 | Press Releases
Advancing Dyadic’s proprietary owned COVID-19 vaccine candidate, DYAI-100, towards first-in-human Phase 1 clinical trialEngaged CR2O, a contract research organization, to manage and support further pre-clinical and clinical developmentTo validate C1 produced...
by B2i | Mar 22, 2021 | Press Releases
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g.,...
by B2i | Mar 18, 2021 | Press Releases
Israel Institute for Biological Research (IIBR) reports successful challenge studies using human ACE2 transgenic mice vaccinated with SARS-CoV-2-S-RBD vaccine candidate manufactured from C1-cellsDYAI-100 generated high levels of neutralizing antibodies in preclinical...
